$3.48
0.29% today
Nasdaq, Apr 01, 07:17 pm CET
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Arbutus Biopharma Corporation Stock price

$3.49
+0.04 1.16% 1M
-0.36 9.35% 6M
+0.22 6.73% YTD
+0.93 36.33% 1Y
+0.51 17.11% 3Y
+2.48 245.54% 5Y
-13.97 80.01% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.01 0.29%
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Key metrics

Market capitalization $668.27m
Enterprise Value $551.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 89.43
P/S ratio (TTM) P/S ratio 108.31
P/B ratio (TTM) P/B ratio 6.81
Revenue growth (TTM) Revenue growth -65.98%
Revenue (TTM) Revenue $6.17m
EBIT (operating result TTM) EBIT $-69.97m
Free Cash Flow (TTM) Free Cash Flow $-63.71m
Cash position $122.62m
EPS (TTM) EPS $-0.38
P/E forward negative
P/S forward 106.43
EV/Sales forward 87.87
Short interest 6.41%
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Arbutus Biopharma Corporation forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
75%
Hold
25%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6.17 6.17
66% 66%
100%
- Direct Costs 1.38 1.38
1% 1%
22%
4.79 4.79
71% 71%
78%
- Selling and Administrative Expenses 19 19
2% 2%
314%
- Research and Development Expense 54 54
27% 27%
876%
-69 -69
10% 10%
-1,112%
- Depreciation and Amortization 1.38 1.38
1% 1%
22%
EBIT (Operating Income) EBIT -70 -70
10% 10%
-1,134%
Net Profit -70 -70
4% 4%
-1,133%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Negative
Market Watch
5 days ago
Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.
Neutral
GlobeNewsWire
5 days ago
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending
Neutral
GlobeNewsWire
29 days ago
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on ...
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Lindsay Androski
Employees 44
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today